Exparel Versus Bupivacaine in Post-operative Pain Control

PHASE4CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2025

Conditions
Liposomal Bupivacaine
Interventions
DRUG

Bupivacaine liposome injectable suspension

At the end of the third molar extraction surgical procedure performed under general anesthesia and at least fifteen minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine nerve block (routine for this procedure), all patients will receive bilateral infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel) OR with 3mL of 0.5% bupivacaine with 1:200,000 epinephrine while they are still under general anesthesia.

Trial Locations (1)

44106

Case Western Reserve University, Cleveland

All Listed Sponsors
lead

Case Western Reserve University

OTHER

NCT06547255 - Exparel Versus Bupivacaine in Post-operative Pain Control | Biotech Hunter | Biotech Hunter